Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 25/02/2025

Debbie Rigby rounds up the latest in research news Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide? Glucagon-like peptide-1 (GLP-1) agonists are a second line treatment for people with type 2 diabetes, used when diet, exercise, and oral tablets such as metformin are not fully effective for controlling blood glucose levels. Studies

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Research Roundup

Previous Hospital pharmacist named Tassie Intern of the Year

Next Pharmacists at ‘breaking point’

MENU

ajp.com.au

Previous Hospital pharmacist named Tassie Intern of the Year

Next Pharmacists at ‘breaking point’

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.